PolyPeptide Group AG takes note of market rumors and speculation
Baar, 14 April 2026 – PolyPeptide Group AG (SIX: PPGN) (“PolyPeptide” or the “Company”), a specialized global CDMO for peptide-based active pharmaceutical ingredients, takes note of recent market speculation and media reports according to which PolyPeptide has attracted takeover interest from certain investors. As a matter of policy, PolyPeptide does not comment on rumors and speculations.
As part of its fiduciary duties, the Board of Directors regularly assesses the Company’s strategic positioning and options to further enhance long-term value creation. In this context, the Board of Directors, in coordination with the Company’s majority shareholder, Draupnir Holding B.V., is conducting a review of potential strategic options. The review is at an early stage, and no decision has been made. There can be no assurances that the review will continue or that it will result in any transaction or other outcome.
The Company remains focused on executing its strategic plan to deliver long-term value for shareholders, customers, and other stakeholders. It is well positioned to advance toward its ambition of doubling 2023 revenue by 2028, supported by the strong growth potential reflected in its 2026 guidance.
[…]